Infect Chemother.  2013 Sep;45(3):325-330. 10.3947/ic.2013.45.3.325.

Risk Factors for Mortality in Patients with Acinetobacter baumannii Bacteremia

• Park SY
• Choo JW
• Kwon SH
• Yu SN
• Lee EJ
• Kim TH
• Choo EJ
• Jeon MH

• KMID: 2170432
• DOI: http://doi.org/10.3947/ic.2013.45.3.325

Abstract

BACKGROUND
Acinetobacter baumannii, an opportunistic nosocomial pathogen that can cause significant morbidity and mortality, has emerged as a worldwide problem. The aim of this study was to evaluate the risk factors for mortality in patients with A. baumannii bacteremia.
MATERIALS AND METHODS
We retrospectively evaluated 118 patients who had A. baumannii bacteremia between July 2003 and December 2011. The aim of this study was to identify the 30-day mortality in patients with A. baumannii bacteremia and relevant risk factors.
RESULTS
The bacteremia-related 30-day mortality rate was 34.1%. Univariate analysis revealed that the risk factors for mortality included malignancy, longer hospital stay before bacteremia, intensive care unit (ICU) stay at the time of bacteremia, mechanical ventilation, use of a central venous catheter, unknown origin of bacteremia, bacteremia due to pneumonia, antimicrobial resistance to carbapenems, and elevated Acute Physiology and Chronic Health Evaluation II and Pitt bacteremia scores. Multivariate logistic regression analysis revealed that resistance to carbapenems (odds ratio [OR]: 4.01, 95% confidence interval [CI]: 1.51 to 0.68, P = 0.005), need for mechanical ventilation (OR: 3.97, 95% CI: 1.41 to 11.13, P = 0.005), and presence of malignancy (OR: 4.40, 95% CI: 1.60 to 12.08, P = 0.004) were significantly related to mortality risk.
CONCLUSIONS
Risk factors such as resistance to carbapenems, mechanical ventilation, and presence of malignancy were found to be associated with high mortality rates in the patients with A. baumannii bacteremia.

Keyword

Acinetobacter baumannii; Bacteremia; Mortality

MeSH Terms

Acinetobacter
Acinetobacter baumannii
APACHE
Bacteremia
Carbapenems
Central Venous Catheters
Humans
Intensive Care Units
Length of Stay
Logistic Models
Pneumonia
Respiration, Artificial
Retrospective Studies
Risk Factors
Carbapenems

Reference

1. Jeon MH, Park WB, Kim SR, Chun HK, Han SH, Bang JH, Park ES, Jeong SY, Eom JS, Kim YK, Kim HB, Lee KY, Choi HJ, Kim HY, Kim KM, Sung JH, Uh Y, Chung HS, Kwon JW, Woo JH. Korean nosocomial infections surveillance system, intensive care unit module report: data summary from July 2010 through June 2011. Korean J Nosocomial Infect Control. 2012; 17:28–39.

2. Blot S, Vandewoude K, Colardyn F. Nosocomial bacteremia involving Acinetobacter baumannii in critically ill patients: a matched cohort study. Intensive Care Med. 2003; 29:471–475.

3. Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis. 2008; 46:1254–1263.

4. Tseng YC, Wang JT, Wu FL, Chen YC, Chie WC, Chang SC. Prognosis of adult patients with bacteremia caused by extensively resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis. 2007; 59:181–190.

5. Kim SY, Jung JY, Kang YA, Lim JE, Kim EY, Lee SK, Park SC, Chung KS, Park BH, Kim YS, Kim SK, Chang J, Park MS. Risk factors for occurrence and 30-day mortality for carbapenem-resistant Acinetobacter baumannii bacteremia in an intensive care unit. J Korean Med Sci. 2012; 27:939–947.

6. Cisneros JM, Reyes MJ, Pachón J, Becerril B, Caballero FJ, García-Garmendía JL, Ortiz C, Cobacho AR. Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis. 1996; 22:1026–1032.

7. Wareham DW, Bean DC, Khanna P, Hennessy EM, Krahe D, Ely A, Millar M. Bloodstream infection due to Acinetobacter spp: epidemiology, risk factors and impact of multi-drug resistance. Eur J Clin Microbiol Infect Dis. 2008; 27:607–612.

8. Kim YJ, Kim SI, Hong KW, Kim YR, Park YJ, Kang MW. Risk factors for mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia: impact of appropriate antimicrobial therapy. J Korean Med Sci. 2012; 27:471–475.

9. Sheng WH, Liao CH, Lauderdale TL, Ko WC, Chen YS, Liu JW, Lau YJ, Wang LH, Liu KS, Tsai TY, Lin SY, Hsu MS, Hsu LY, Chang SC. A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant Acinetobacter baumannii. Int J Infect Dis. 2010; 14:e764–e769.

10. Wikler MA. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved Standard. 8th ed. Wayne, Pa: CLSI;2008.

11. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988; 16:128–140.

12. Lee NY, Lee HC, Ko NY, Chang CM, Shih HI, Wu CJ, Ko WC. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol. 2007; 28:713–719.

13. Lee YT, Kuo SC, Yang SP, Lin YT, Tseng FC, Chen TL, Fung CP. Impact of appropriate antimicrobial therapy on mortality associated with Acinetobacter baumannii bacteremia: relation to severity of infection. Clin Infect Dis. 2012; 55:209–215.

14. Choi JY, Park YS, Kim CO, Park YS, Yoon HJ, Shin SY, Kim YA, Song YG, Yong D, Lee K, Kim JM. Mortality risk factors of Acinetobacter baumannii bacteraemia. Intern Med J. 2005; 35:599–603.

15. Routsi C, Pratikaki M, Platsouka E, Sotiropoulou C, Nanas S, Markaki V, Vrettou C, Paniara O, Giamarellou H, Roussos C. Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes. Infection. 2010; 38:173–180.

16. Cisneros JM, Rodríguez-Baño J. Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment. Clin Microbiol Infect. 2002; 8:687–693.